Tuberculosis and anti‐tuberculosis treatments cannot be ignored when evaluating cirrhotic patients co‐infected with HIV or not

Abstract

Study conducted by Salmon‐Ceron, D. et al. ^[1shows that in the period of combined antiretroviral therapy, the risks of hepatocellular carcinoma(HCC) and hepatic decompensation are similar between HCV mono‐infected cirrhotic patients and HIV/HCV co‐infected cirrhotic patients, even though the later have higher all‐cause mortality. Although rigorously implemented, the study overlooked tuberculosis infections and anti‐tuberculosis therapy, which may greatly influence the outcome.

This article is protected by copyright. All rights reserved.

https://ift.tt/2NvdCl2